John W.M. Martens

49.9k citations

328 papers · 11.9k indexed · 2 hit papers · h-index 61

Molecular Biology top 0.5%
Cancer Research top 0.1%
Oncology top 0.5%
Pulmonary and Respiratory Medicine top 1%
Genetics top 1%

Co-authors: John A. Foekens Anieta M. Sieuwerts Marcel Smid Stefan Sleijfer Jan G.M. Klijn Maxime P. Look Yixin Wang Vanja de Weerd
Topics: Cancer Genomics and Diagnostics (106 papers)Cancer Cells and Metastasis (52 papers)BRCA gene mutations in cancer (27 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Journal of Clinical Investigation
Partner nations: Netherlands United States Germany

In The Last Decade

John W.M. Martens

315 papers receiving 11.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Subtypes of Breast Cancer Show Preferential Site of Relapse

2008 622 citations Marcel Smid, Yixin Wang et al. Cancer Research profile →
Pan-cancer landscape of homologous recombination deficiency

2020 277 citations John W.M. Martens, Edwin Cuppen et al. profile →

Peers

Countries citing papers authored by John W.M. Martens

Since Specialization

Citations

This map shows the geographic impact of John W.M. Martens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John W.M. Martens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John W.M. Martens more than expected).

Fields of papers citing papers by John W.M. Martens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John W.M. Martens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John W.M. Martens. The network helps show where John W.M. Martens may publish in the future.

Co-authorship network of co-authors of John W.M. Martens

This figure shows the co-authorship network connecting the top 25 collaborators of John W.M. Martens. A scholar is included among the top collaborators of John W.M. Martens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John W.M. Martens. John W.M. Martens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels 2023 ·Scientific Reports ·Elisabeth M. Jongbloed,Maurice P.H.M. Jansen,Vanja de Weerd,(unknown),Corine M. Beaufort,Marcel Reinders,Ronald van Marion,Wilfred F. J. van IJcken,Gabe S. Sonke,Inge R. Konings,Agnes Jager,John W.M. Martens,Saskia M. Wilting,(unknown)	2
2	mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer 2023 ·Molecular Oncology ·(unknown),Bianca Mostert,(unknown),Jaco Kraan,Vanja de Weerd,Esther Oomen‐de Hoop,Paul Hamberg,Brigitte C.M. Haberkorn,Helgi H. Helgason,Ronald de Wit,Ron H.J. Mathijssen,Martijn P. Lolkema,Saskia M. Wilting,Job van Riet,John W.M. Martens	5
3	Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling 2023 ·Cancers ·Lindsay Angus,Marcel Smid,Saskia M. Wilting,(unknown),Neeltje Steeghs,Inge R. Konings,Vivianne C. G. Tjan‐Heijnen,J.M.G.H. van Riel,Agnès J. van de Wouw,Edwin Cuppen,Martijn P. Lolkema,Agnes Jager,Stefan Sleijfer,John W.M. Martens	3
4	Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast 2019 ·Journal of Clinical Pathology ·Marijn A. Vermeulen,Rob B. van der Luijt,Carolien P. Schröder,John W.M. Martens,P. J. van Diest	3
5	Polyomavirus T Antigen Induces APOBEC3B Expression Using an LXCXE-Dependent and TP53-Independent Mechanism 2019 ·mBio ·Gabriel J. Starrett,Artur A. Serebrenik,(unknown),Jennifer L. McCann,Brandy Verhalen,Matthew C. Jarvis,Teneale A. Stewart,Emily K. Law,(unknown),Mengxi Jiang,John W.M. Martens,Ellen Cahir-McFarland,Paul N. Span,Reuben S. Harris	32
6	Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes 2019 ·Clinical Cancer Research ·Dora Hammerl,Maarten P.G. Massink,Marcel Smid,Carolien H. M. van Deurzen,Hanne Meijers‐Heijboer,Quinten Waisfisz,Reno Debets,John W.M. Martens	37
7	Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer 2018 ·Clinical Cancer Research ·(unknown),Marcel Smid,Anika Nagelkerke,John W.M. Martens,Johan Bussink,Fred C.G.J. Sweep,Paul N. Span	64
8	Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects 2018 ·Clinical Cancer Research ·Titia G. Meijer,Nicole S. Verkaik,Anieta M. Sieuwerts,Job van Riet,Kishan A.T. Naipal,Carolien H. M. van Deurzen,Michael A. den Bakker,Hein F.B.M. Sleddens,(unknown),(unknown),Winand N.M. Dinjens,Esther H. Lips,Petra M. Nederlof,Marcel Smid,Harmen J.G. van de Werken,Roland Kanaar,John W.M. Martens,Agnes Jager,Dik C. van Gent	47
9	A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer 2017 ·Cancer Research ·Wigard P. Kloosterman,Robert R.J. Coebergh van den Braak,Mark Pieterse,Markus J. van Roosmalen,Anieta M. Sieuwerts,(unknown),(unknown),Zarina S. Lalmahomed,Salo Ooft,Anne van Galen,Marcel Smid,(unknown),Fried Zwartkruis,John W.M. Martens,John A. Foekens,Katharina Biermann,Marco J. Koudijs,Jan N.M. IJzermans,Emile E. Voest	67
10	Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy 2017 ·Clinical Cancer Research ·Marjolein J.A. Weerts,Antoinette Hollestelle,Anieta M. Sieuwerts,John A. Foekens,Stefan Sleijfer,John W.M. Martens	16
11	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma 2016 ·Clinical Cancer Research ·Brandon Leonard,Gabriel J. Starrett,Matthew J. Maurer,Ann L. Oberg,Mieke Van Bockstal,Jo Van Dorpe,Olivier De Wever,Jozien Helleman,Anieta M. Sieuwerts,Els M.J.J. Berns,John W.M. Martens,Brett D. Anderson,William L. Brown,Kimberly R. Kalli,Scott H. Kaufmann,Reuben S. Harris	52
12	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy 2014 ·Molecular Cancer Therapeutics ·Wendy Onstenk,Jaco Kraan,Bianca Mostert,(unknown),Ayoub Charehbili,Vincent T.H.B.M. Smit,Judith R. Kroep,J.W.R. Nortier,Saskia van de Ven,Joan B. Heijns,Lonneke W. Kessels,Hanneke W.M. van Laarhoven,Monique M.E.M. Bos,Cornelis J.�H. van de Velde,Jan W. Gratama,Anieta M. Sieuwerts,John W.M. Martens,John A. Foekens,Stefan Sleijfer	47
13	Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways 2014 ·Cancer Research ·Wim Verhaegh,(unknown),Márcia A. Inda,Pantelis Hatzis,Rogier Versteeg,Marcel Smid,John W.M. Martens,John A. Foekens,(unknown),Hans Clevers,Anja van de Stolpe	62
14	Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment 2014 ·Clinical Cancer Research ·Kishan A.T. Naipal,Nicole S. Verkaik,Najim Ameziane,Carolien H. M. van Deurzen,Petra ter Brugge,Matty Meijers,Anieta M. Sieuwerts,John W.M. Martens,Mark J. O’Connor,Harry Vrieling,Jan H.J. Hoeijmakers,Jos Jonkers,Roland Kanaar,Johan P. de Winter,Maaike P.G. Vreeswijk,Agnes Jager,Dik C. van Gent	124
15	Validation of a Radiosensitivity Molecular Signature in Breast Cancer 2012 ·Clinical Cancer Research ·Steven A. Eschrich,William J. Fulp,Yudi Pawitan,John A. Foekens,Marcel Smid,John W.M. Martens,Michelle Echevarria,Vidya Kamath,Ji‐Hyun Lee,Eleanor Harris,Jonas Bergh,Javier F. Torres–Roca	145
16	FOXC1 Is a Potential Prognostic Biomarker with Functional Significance in Basal-like Breast Cancer 2010 ·Cancer Research ·Partha Ray,Jinhua Wang,Ying Qu,Myung‐Shin Sim,Jaime Shamonki,Sanjay P. Bagaria,Xing Ye,Bingya Liu,David Elashoff,Dave S.�B. Hoon,Michael A. Walter,John W.M. Martens,Andrea L. Richardson,Armando E. Giuliano,Xiaojiang Cui	199
17	Copy Number Alterations that Predict Metastatic Capability of Human Breast Cancer 2009 ·Cancer Research ·Yi Zhang,John W.M. Martens,Jack X. Yu,John Jiang,Anieta M. Sieuwerts,Marcel Smid,Jan G.M. Klijn,Yixin Wang,John A. Foekens	70
18	DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy 2008 ·Clinical Cancer Research ·Oliver Hartmann,Frédérique Spyratos,Nadia Harbeck,Dimo Dietrich,(unknown),Manfred Schmitt,Serenella Eppenberger‐Castori,Vincent Vuaroqueaux,Florence Lerebours,Katrin Welzel,Sabine Maier,Achim Plum,Stephan Niemann,John A. Foekens,Ralf Lesche,John W.M. Martens	79
19	Subtypes of Breast Cancer Show Preferential Site of Relapsebreakdown → 2008 ·Cancer Research ·Marcel Smid,Yixin Wang,Yi Zhang,Anieta M. Sieuwerts,Jack X. Yu,Jan G.M. Klijn,John A. Foekens,John W.M. Martens	622
20	Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer 2005 ·Cancer Research ·John W.M. Martens,Inko Nimmrich,Thomas Koenig,Maxime P. Look,Nadia Harbeck,Fabian Model,(unknown),Joan Bolt‐de Vries,Anieta M. Sieuwerts,Henk Portengen,Marion E. Meijer‐van Gelder,Christian Piepenbrock,Alexander Olek,Heinz Höfler,Marion Kiechle,Jan G.M. Klijn,Manfred Schmitt,Sabine Maier,John A. Foekens	102

About John W.M. Martens

John W.M. Martens is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 328 papers that have together received 11.9k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (106 papers), Cancer Cells and Metastasis (52 papers) and BRCA gene mutations in cancer (27 papers). The work is most often cited by research in Cancer Research (4.8k citations), Oncology (4.4k citations) and Molecular Biology (6.8k citations). John W.M. Martens has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include John A. Foekens, Anieta M. Sieuwerts, Marcel Smid, Stefan Sleijfer, Jan G.M. Klijn, Maxime P. Look, Yixin Wang, Vanja de Weerd, Jaco Kraan and Jack X. Yu. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact